ADOCIA Reports Fourth Quarter 2024 Financial Results and Provides a Business Update
Cash position of €7.5 million as of December 31, 2024 BioChaperone Lispro final dosing of Phase 3 triggered a $10 million revenue recognition, and top-line data are expected in mid-2025 ...